HilleVax announced that it intends to offer and sell, subject to market and other conditions, $100M of shares of its common stock in an underwritten public offering. All of the shares are being offered by HilleVax. HilleVax intends to use the net proceeds from the proposed offering to fund the clinical development of HIL-214, including certain manufacturing activities, and for working capital and general corporate purposes. J.P. Morgan, Leerink Partners, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HLVX:
- HilleVax Announces Pricing of Public Offering of Common Stock
- HilleVax Announces Proposed Public Offering of Common Stock
- J.P. Morgan Sees up to 110% Gains in These 2 Stocks — Here’s Why They Could Soar
- HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
- HilleVax reports Q2 EPS (74c), consensus (90c)
